Blinded SAPS-PD Assessment After 10 Weeks of Pimavanserin Treatment for Parkinson’s Disease Psychosis

BACKGROUND: Parkinson’s disease psychosis (PDP) is a common nonmotor symptom that affects up to 60% of patients. Pimavanserin, a selective 5-HT(2A) inverse agonist/antagonist, is approved for treating hallucinations and delusions associated with PDP. OBJECTIVE: Evaluate the efficacy and tolerability...

Descripción completa

Detalles Bibliográficos
Autores principales: Isaacson, Stuart H., Coate, Bruce, Norton, James, Stankovic, Srdjan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2020
Materias:
Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7683065/
https://www.ncbi.nlm.nih.gov/pubmed/32716320
http://dx.doi.org/10.3233/JPD-202047

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7683065/
https://www.ncbi.nlm.nih.gov/pubmed/32716320
http://dx.doi.org/10.3233/JPD-202047

Ejemplares similares